News coverage about Celyad SA (NASDAQ:CYAD) has trended positive on Friday, according to AlphaOne Sentiment. The research group, a unit of Accern, identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celyad SA earned a media sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave news stories about the company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
Shares of Celyad SA (NASDAQ:CYAD) traded up 2.66% during trading on Friday, hitting $40.58. 786 shares of the stock traded hands. The firm’s market capitalization is $386.32 million. The firm has a 50-day moving average of $33.26 and a 200-day moving average of $23.56. Celyad SA has a 1-year low of $16.31 and a 1-year high of $59.50.
ILLEGAL ACTIVITY NOTICE: “Celyad SA (CYAD) Getting Favorable Media Coverage, Report Shows” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/19/celyad-sa-cyad-earning-favorable-news-coverage-report-finds-updated.html.
Celyad SA Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.